The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

Trump administration funding cuts and dismantling of USAID force the focus to shift from elimination back to treatment.

Twice-yearly lenacapavir injection provides 100% protection from HIV when used as PrEP in cisgender women, says Gilead.

Globally, 1.3 million people were newly infected with HIV in 2023, according to the latest estimates. But getting lenacapavir to low- and middle-income countries may take time.

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...